Targeted preventive measures and advanced approaches in personalised treatment of glaucoma neuropathy

EPMA Journal

Volumn 1, Issue 2, 2010, Pages 229-235

  Mozaffarieh, Maneli ^a   Fraenkl, Stefan ^a   Konieczka, Katarzyna ^a   Flammer, Josef ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Glaucomatous optic neuropathy; Oxidative stress; Personalised; Preventive; Vascular regulation

Indexed keywords

ACETAZOLAMIDE; ANTHOCYANIN; CALCIUM CHANNEL BLOCKING AGENT; DIPYRIDAMOLE; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FLAVONOID; GELATINASE B; GINKGO BILOBA EXTRACT; HEAT SHOCK PROTEIN; ILOMASTAT; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX METALLOPROTEINASE; MELATONIN; OMEGA 3 FATTY ACID; PLACEBO; TEPRENONE; THEOBROMA OIL; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE;

ANTIOXIDANT ACTIVITY; ASTROCYTE; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; EYE BLOOD FLOW; GLAUCOMA; GLAUCOMA NEUROPATHY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MECHANICAL STRESS; NEUROPATHOLOGY; NONHUMAN; OPTIC NERVE; OPTIC NERVE DISEASE; OPTIC NERVE LESION; OXIDATIVE STRESS; OXYGEN SUPPLY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS REGULATION; RETINA GANGLION CELL; REVIEW; UPREGULATION; VISUAL FIELD;

EID: 79953040518     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0018-1     Document Type: Review

References (68)

1. Flammer J, Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy? Surv Ophthalmol. 2007; 52 Suppl 2: S162-73.
2. Hernandez MR, Agapova OA, Yang P, Salvador-Silva M, Ricard CS, Aoi S. Differential gene expression in astrocytes from human normal and glaucomatous optic nerve head analyzed by cDNA microarray. Glia. 2002; 38: 45-64.
3. Zhang X, Neufeld AH. Activation of the epidermal growth factor receptor in optic nerve astrocytes leads to early and transient induction of cyclooxygenase-2. Invest Ophthalmol Vis Sci. 2005; 46: 2035-41.
4. Hashimoto K, Parker A, Malone P, Gabelt BT, Rasmussen C, Kaufman PS, et al. Long-term activation of c-Fos and c-Jun in optic nerve head astrocytes in experimental ocular hypertension in monkeys and after exposure to elevated pressure in vitro. Brain Res. 2005; 1054: 103-15.
5. Liu B, Chen H, Johns TG, Neufeld AH. Epidermal growth factor receptor activation: an upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury. J Neurosci. 2006; 26: 7532-40.
6. Neufeld AH, Liu B. Glaucomatous optic neuropathy: when glia misbehave. Neuroscientist. 2003; 9: 485-95.
7. Emre M, Orgul S, Haufschild T, Shaw SG, Flammer J. Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma. Br J Ophthalmol. 2005; 89: 60-3.
8. Stokely ME, Yorio T, King MA. Endothelin-1 modulates anterograde fast axonal transport in the central nervous system. J Neurosci Res. 2005; 79: 598-607.
9. Taniguchi T, Shimazawa M, Sasaoka M, Shimazaki A, Hara H. Endothelin-1 impairs retrograde axonal transport and leads to axonal injury in rat optic nerve. Curr Neurovasc Res. 2006; 3: 81-8.
10. Prasanna G, Krishnamoorthy R, Clark AF, Wordinger RJ, Yorio T. Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci. 2002; 43: 2704-13.
11. Grieshaber MC, Terhorst T, Flammer J. The pathogenesis of optic disc splinter haemorrhages: a new hypothesis. Acta Ophthalmol Scand. 2006; 84: 62-8.
12. Grieshaber MC, Orgul S, Schoetzau A, Flammer J. Relationship between retinal glial cell activation in glaucoma and vascular dysregulation. J Glaucoma. 2007; 16: 215-9.
13. Dettmann ES, Luscher TF, Flammer J, Haefliger IO. Modulation of endothelin-1-induced contractions by magnesium/calcium in porcine ciliary arteries. Graefes Arch Clin Exp Ophthalmol. 1998; 236: 47-51.
14. Gaspar AZ, Flammer J, Hendrickson P. Influence of nifedipine on the visual fields of patients with optic-nerve-head diseases. Eur J Ophthalmol. 1994; 4: 24-8.
15. Gaspar AZ, Gasser P, Flammer J. The influence of magnesium on visual field and peripheral vasospasm in glaucoma. Ophthalmologica. 1995; 209: 11-3.
16. Gasser P, Flammer J. Short- and long-term effect of nifedipine on the visual field in patients with presumed vasospasm. J Int Med Res. 1990; 18: 334-9.
17. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986; 232: 1629-32.
18. Neufeld AH, Sawada A, Becker B. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc Natl Acad Sci USA. 1999; 96: 9944-8.
19. Kaiser HJ, Flammer J. Systemic hypotension: a risk factor for glaucomatous damage? Ophthalmologica. 1991; 203: 105-8.
20. Tokunaga T, Kashiwagi K, Tsumura T, Taguchi K, Tsukahara S. Association between nocturnal blood pressure reduction and progression of visual field defect in patients with primary open-angle glaucoma or normal-tension glaucoma. Jpn J Ophthalmol. 2004; 48: 380-5.
21. Pechere-Bertschi A, Nussberger J, Biollaz J, Fahti M, Grouzmann E, Morgan T, et al. Circadian variations of renal sodium handling in patients with orthostatic hypotension. Kidney Int. 1998; 54: 1276-82.
22. Gugleta K, Orgul S, Stumpfig D, Dubler B, Flammer J. Fludrocortisone in the treatment of systemic hypotension in primary open-angle glaucoma patients. Int Ophthalmol. 1999; 23: 25-30.
23. Flammer J, Haefliger IO, Orgul S, Resink T. Vascular dysregulation: a principal risk factor for glaucomatous damage? J Glaucoma. 1999; 8: 212-9.
24. Nagel E, Vilser W, Lanzl I. Dorzolamide influences the autoregulation of major retinal vessels caused by artificial intraocular pressure elevation in patients with POAG: a clinical study. Curr Eye Res. 2005; 30: 129-37.
25. Flammer J, Orgul S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002; 21: 359-93.
26. Flammer J, Drance SM. Reversibility of a glaucomatous visual field defect after acetazolamide therapy. Can J Ophthalmol. 1983; 18: 139-41.
27. Flammer J, Drance SM. Effect of acetazolamide on the differential threshold. Arch Ophthalmol. 1983; 101: 1378-80.
28. Paterson G. Effect of intravenous acetazolamide on relative arcuate scotomas and visual field in glaucoma simplex. Proc R Soc Med. 1970; 63: 865-9.
29. Guthauser U, Flammer J, Mahler F. The relationship between digital and ocular vasospasm. Graefes Arch Clin Exp Ophthalmol. 1988; 226: 224-6.
30. Pillunat LE, Lang GK, Harris A. The visual response to increased ocular blood flow in normal pressure glaucoma. Surv Ophthalmol. 1994; 38(Suppl): S139-47.
31. Kitazawa Y, Shirai H, Go FJ. The effect of Ca2(+) -antagonist on visual field in low-tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 1989; 227: 408-12.
32. Strenn K, Matulla B, Wolzt M, Findl O, Bekes MC, Lamsfuss U, et al. Reversal of endothelin-1-induced ocular hemodynamic effects by low-dose nifedipine in humans. Clin Pharmacol Ther. 1998; 63: 54-63.
33. Meyer P, Flammer J, Luscher TF. Effect of dipyridamole on vascular responses of porcine ciliary arteries. Curr Eye Res. 1996; 15: 387-93.
34. Kaiser HJ, Stumpfig D, Flammer J. Short-term effect of dipyridamole on blood flow velocities in the extraocular vessels. Int Ophthalmol. 1995; 19: 355-8.
35. Engler MB. Vascular relaxation to omega-3 fatty acids: comparison to sodium nitroprusside, nitroglycerin, papaverine, and D600. Cardiovasc Drugs Ther. 1992; 6: 605-10.
36. Cha SH, Fukushima A, Sakuma K, Kagawa Y. Chronic docosahexaenoic acid intake enhances expression of the gene for uncoupling protein 3 and affects pleiotropic mRNA levels in skeletal muscle of aged C57BL/6NJcl mice. J Nutr. 2001; 131: 2636-42.
37. Hun CS, Hasegawa K, Kawabata T, Kato M, Shimokawa T, Kagawa Y. Increased uncoupling protein2 mRNA in white adipose tissue, and decrease in leptin, visceral fat, blood glucose, and cholesterol in KK-Ay mice fed with eicosapentaenoic and docosahexaenoic acids in addition to linolenic acid. Biochem Biophys Res Commun. 1999; 259: 85-90.
38. Karim M, McCormick K, Kappagoda CT. Effects of cocoa extracts on endothelium-dependent relaxation. J Nutr. 2000; 130: 2105S-8.
39. Flammer J. Glaucomatous optic neuropathy: a reperfusion injury. Klin Monatsbl Augenheilkd. 2001; 218: 290-1.
40. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res. 2006; 25: 490-513.
41. Sacca SC, Pascotto A, Camicione P, Capris P, Izzotti A. Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol. 2005; 123: 458-63.
42. Tamm ER, Russell P, Johnson DH, Piatigorsky J. Human and monkey trabecular meshwork accumulate alpha B-crystallin in response to heat shock and oxidative stress. Invest Ophthalmol Vis Sci. 1996; 37: 2402-13.
43. Abu-Amero KK, Morales J, Bosley TM. Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2006; 47: 2533-41.
44. Eckert A, Keil U, Kressmann S, Schindowski K, Leutner S, Leutz S, et al. Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsychiatry. 2003; 36 Suppl 1: S15-23.
45. Eckert A, Keil U, Scherping I, Hauptmann S, Muller WE. Stabilization of mitochondrial membrane potential and improvement of neuronal energy metabolism by Ginkgo Biloba Extract EGb 761. Ann N Y Acad Sci. 2005; 1056: 474-85.
46. Ritch R. Potential role for Ginkgo biloba extract in the treatment of glaucoma. Med Hypotheses. 2000; 54: 221-35.
47. Sener G, Sener E, Sehirli O, Ogunc AV, Cetinel S, Gedik N, et al. Ginkgo biloba extract ameliorates ischemia reperfusion-induced renal injury in rats. Pharmacol Res. 2005; 52: 216-22.
48. Quaranta L, Bettelli S, Uva MG, Semeraro F, Turano R, Gandolfo E. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology. 2003; 110: 359-62.
49. Le Bars PL, Kastelan J. Efficacy and safety of a Ginkgo biloba extract. Public Health Nutr. 2000; 3: 495-9.
50. Mozaffarieh M, Grieshaber MC, Orgul S, Flammer J. The potential value of natural antioxidative treatment in glaucoma. Surv Ophthalmol. 2008; 53: 479-505.
51. Mozaffarieh M, Flammer J. A novel perspective on natural therapeutic approaches in glaucoma therapy. Expert Opin Emerg Drugs. 2007; 12: 195-8.
52. Mozaffarieh M, Flammer J. Is there more to glaucoma treatment than lowering IOP? Surv Ophthalmol. 2007; 52 Suppl 2: S174-9.
53. Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol. 2006; 545: 51-64.
54. Wei H, Zhang X, Zhao JF, Wang ZY, Bickers D, Lebwohl M. Scavenging of hydrogen peroxide and inhibition of ultraviolet light-induced oxidative DNA damage by aqueous extracts from green and black teas. Free Radic Biol Med. 1999; 26: 1427-35.
55. Kim AR, Zou Y, Kim HS, Choi JS, Chang GY, Kim YJ, et al. Selective peroxynitrite scavenging activity of 3-methyl-1, 2-cyclopentanedione from coffee extract. J Pharm Pharmacol. 2002; 54: 1385-92.
56. Miller KB, Stuart DA, Smith NL, Lee CY, McHale NL, Flanagan JA, et al. Antioxidant activity and polyphenol and procyanidin contents of selected commercially available cocoa-containing and chocolate products in the United States. J Agric Food Chem. 2006; 54: 4062-8.
57. Haufschild T, Kaiser HJ, Preisig T, Pruente C, Flammer J. Influence of red wine on visual function and endothelin-1 plasma level in a patient with optic neuritis. Ann Neurol. 2003; 53: 825-6.
58. Maatta-Riihinen KR, Kahkonen MP, Torronen AR, Heinonen IM. Catechins and procyanidins in berries of vaccinium species and their antioxidant activity. J Agric Food Chem. 2005; 53: 8485-91.
59. Tomasetti M, Alleva R, Borghi B, Collins AR. In vivo supplementation with coenzyme Q10 enhances the recovery of human lymphocytes from oxidative DNA damage. FASEB J. 2001; 15: 1425-7.
60. Allegra M, Reiter RJ, Tan DX, Gentile C, Tesoriere L, Livrea MA. The chemistry of melatonin's interaction with reactive species. J Pineal Res. 2003; 34: 1-10.
61. Siu AW, Maldonado M, Sanchez-Hidalgo M, Tan DX, Reiter RJ. Protective effects of melatonin in experimental free radical-related ocular diseases. J Pineal Res. 2006; 40: 101-9.
62. Agapova OA, Ricard CS, Salvador-Silva M, Hernandez MR. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human optic nerve head astrocytes. Glia. 2001; 33: 205-16.
63. Golubnitschaja O, Yeghiazaryan K, Liu R, Monkemann H, Leppert D, Schild H, et al. Increased expression of matrix metalloproteinases in mononuclear blood cells of normal-tension glaucoma patients. J Glaucoma. 2004; 13: 66-72.
64. Manabe S, Gu Z, Lipton SA. Activation of matrix metalloproteinase-9 via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death. Invest Ophthalmol Vis Sci. 2005; 46: 4747-53.
65. Chintala SK, Zhang X, Austin JS, Fini ME. Deficiency in matrix metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell death after optic nerve ligation. J Biol Chem. 2002; 277: 47461-8.
66. Ishii Y, Kwong JM, Caprioli J. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2003; 44: 1982-92.
67. Strenn K, Matulla B, Wolzt M, Findl O, Bekes MC, Lamsfuss U, et al. Reversal of endothelin-1-induced ocular hemodynamic effects by low-dose nifedipine in humans. Clin Pharmacol Ther. 1998; 63: 54-63.
68. Ritch R. Neuroprotection: is it already applicable to glaucoma therapy? Curr Opin Ophthalmol. 2000; 11: 78-84.